SciSparc Meeting Adjourned Due to Lack of Quorum
Ticker: SPRC · Form: 6-K · Filed: Aug 25, 2025 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Aug 25, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: meeting-adjournment, acquisition, share-issuance
TL;DR
SciSparc's shareholder meeting pushed a day due to no-shows; key votes on Therapix deal and share issuance are now tomorrow.
AI Summary
SciSparc Ltd. convened its Special General Meeting of Shareholders on August 25, 2025, but it was adjourned for one day due to a lack of quorum. The meeting will reconvene on August 26, 2025, at the same time and location to address matters including the proposed acquisition of all outstanding shares of Therapix Biosciences Ltd. and the potential issuance of up to 10,000,000 ordinary shares.
Why It Matters
The adjournment delays crucial shareholder decisions regarding the Therapix acquisition and share issuance, potentially impacting SciSparc's strategic direction and financial structure.
Risk Assessment
Risk Level: medium — The adjournment due to lack of quorum indicates potential shareholder disinterest or logistical issues, which could complicate the approval of significant corporate actions.
Key Numbers
- 10,000,000 — Ordinary Shares (Potential issuance of shares pending shareholder approval.)
Key Players & Entities
- SciSparc Ltd. (company) — Registrant
- August 25, 2025 (date) — Date of initial Special General Meeting
- August 26, 2025 (date) — Date of reconvened Special General Meeting
- Therapix Biosciences Ltd. (company) — Company to be acquired
- 10,000,000 ordinary shares (dollar_amount) — Number of shares potentially to be issued
FAQ
Why was the Special General Meeting adjourned?
The meeting was adjourned due to a lack of quorum.
When will the Special General Meeting reconvene?
The meeting will reconvene on August 26, 2025.
What is the primary purpose of the Special General Meeting?
The meeting is to vote on matters including the proposed acquisition of Therapix Biosciences Ltd. and the potential issuance of up to 10,000,000 ordinary shares.
What is SciSparc Ltd.'s principal executive office address?
The address is 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel.
Does SciSparc Ltd. file annual reports under Form 20-F?
Yes, SciSparc Ltd. indicates it files annual reports under Form 20-F.
Filing Stats: 377 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2025-08-25 16:00:21
Filing Documents
- ea0254471-6k_scisparc.htm (6-K) — 12KB
- 0001213900-25-080337.txt ( ) — 13KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: August 25, 2025 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer 2